University of Colorado Anschutz Medical Campus
Operating out of the Department of Psychiatry, Division of Addiction Science, Prevention, and Treatment, “Cannabis, Health, and Addiction Over the lifeSpan” (CHAOS) Lab is directed by Dr. Kent Hutchison, Professor of Psychiatry at CU Anschutz Medical Campus and Director of the nascent Rocky Mountain Cannabis Research Center (RM-CRC).
Our research is focused on understanding how cannabinoids like CBD and THC influence the endocannabinoid system which in turn influences the immune system and the brain. This research has implications for chronic pain, anxiety, sleep, and opioid and alcohol use. There are also important implications of this research for our aging population.
At the CHAOS Lab we have a passion for science, innovative research design, and the translation of research into public health interventions and policy. Our team-based approach is scientifically rigorous and mentorship driven, and we provide opportunities for growth to individuals at all stages of their professional development. We strive for representation in terms of perspective, age, ethnicity, disability status, and gender. We leverage collaborations across disciplines to build a stronger and healthier community for all.
At CHAOS Lab we have a passion for perpetual learning, public dissemination, and innovative research design that improves public health. Our team-based approach is scientifically rigorous and mentorship driven, and we provide opportunity to individuals at all stages of their professional development. We strive to include diversity of representation in terms of perspective, academic background, race, age, ethnicity, disability status, gender, gender identity, sexual orientation, and veteran status. We leverage collaborations across disciplines to build a stronger and healthier community for all.
The CHAOS lab is made up of a highly engaged and collaborative team of researchers. We recognize that diverse teams conduct better research. We foster an environment where team members are treated equally, and where we respect our differences. The team includes faculty, postdocs, students at all levels, and staff.
This study aims to better understand the effects of hemp-derived CBD with and without a small amount of THC, we are conducting a Phase II, 12-week long randomized clinical trial (RTC) to examine the safety, tolerability, and clinical effects of Full Spectrum CBD (fsCBD, contains less than 0.3% THC) vs. Broad Spectrum CBD (bsCBD, does not contain THC) vs. a matching placebo in a population of participants with a moderate Alcohol Use Disorder (AUD) according to the DSM-V. This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of fsCBD and bsCBD, compared to a placebo control, to reduce drinking in a population of AUD subjects.
This study aims to better understand the effects of hemp-derived CBD with and without a small amount of THC, we are conducting a Phase II randomized clinical trial (RCT) to examine the safety, tolerability, and clinical effects of Full Spectrum CBD (fsCBD, contains less than 0.3% THC) vs. Broad Spectrum CBD (bsCBD, does not contain THC), vs. a matching placebo in a population of opioid users. This is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to reduce opioid use, anxiety, and pain and improve sleep and cognitive function.
This study will longitudinally follow 120 individuals 18-60 years with mild to moderate TBI for 12 weeks who are willing to use hemp-derived CBD products. This is a double-blind, placebo-controlled, randomized controlled trial (RCT), such that both the researchers conducting the study condition assignment and clinical assessments and the participant are blind to the condition. We will randomly assign individuals with mild to moderate TBI to either hemp-derived full-spectrum CBD (FS-CBD), which contains low levels of other cannabinoids, CBD alone (CBD), or placebo in a 12-week RCT with measurement of critical indicators occurring at baseline, 6 weeks post-baseline and 12 weeks post-baseline. The dose of CBD in the FS-CBD and CBD conditions is 210mg. We will monitor participant's TBI symptoms while on study medication.
This study investigates the comparison effects of full spectrum hemp-derived CBD (FS-CBD, 200mg), to CBD alone (200mg CBD), and placebo on the primary outcome measures (CDR-SB score, plasma N-p-tau181, plasma Aβ42/Aβ40 ratio, Nfl) and secondary outcome measures (pain, sleep quantity/quality, anxiety) over the course of a 24-week RCT. If you have mild cognitive impairment and would like to help us understand CBD and its effects on cognitive function, see if you are eligible for the study!